Age Related Effects Consuming Phaeodactylum Tricornutum

NCT ID: NCT05120791

Last Updated: 2022-07-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-07-31

Study Completion Date

2022-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigation of the microalgae Phaeodactylum as food with regard to the uptake of omega-3 fatty acids and effects on various blood parameters in relation to age.

Bioavailability and excretion of nutrients and their effects on fatty acid status and inflammatory markers.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Due to a multifaceted redesign of all areas of life, older people face many nutritional challenges, such as cognitive change, sarcopenia and micronutrient deficiency. In addition to age-associated diseases, cognitive decline is usually a precursor to neurodegenerative processes, such as Alzheimer's disease. The full molecular mechanisms are still unknown, but classic aging mechanisms, such as oxidative stress and subclinical inflammation, play a role. Due to the changed life situation, there is a reduced need for energy, while the need for nutrients remains, which greatly increases the risk of malnutrition in old age. This results in an increasing prevalence of sarcopenia. The decrease in muscle mass and strength leads to functional limitations in the elderly and also promotes oxidative stress. This increases the need for antioxidant nutrients such as carotenoids and vitamins. Studies show that age-related chronic subclinical inflammation, such as occurs in the context of an omega-6 fatty acid (-FS) emphasized diet, plays a central role in the pathogenesis of age-associated diseases

Due to this, the microalgae PT could be a goud supplier of nutrients like omega-3 FS, especially eicosapentaenoic acid (EPA), which is otherwise found mainly in fatty fish, and Fucoxanthin, an antioxidant. The investigator study the change of omega-3, -6 and -9 FS in blood plasma, in erythrocytes, as well as the change of fucoxanthin and beta-carotene. The investigator measure blood parameters for safety and control the influence on the intestinal barrier.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aging Well Aging

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

4 arm parallel groups
Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1,3g)

Group Type PLACEBO_COMPARATOR

Placebo vegetable bouillon

Intervention Type DIETARY_SUPPLEMENT

14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1,3g)

Microalgae phaeodactylum

14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae Phaeodactylum

Group Type ACTIVE_COMPARATOR

microalgae phaeodactylum

Intervention Type DIETARY_SUPPLEMENT

14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae Phaeodactylum

Beta-Glucan

14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), Beta-Glucan (1.8g)

Group Type ACTIVE_COMPARATOR

From the Microalgae phaeodactylum the extracted beta-Glucan (especially chrysolaminarin)

Intervention Type DIETARY_SUPPLEMENT

14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), Beta-Glucan (1.8g)

Combi Microalgae phaeodacytlum and Beta-Glucan

14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae, Beta-Glucan (1.8g)

Group Type ACTIVE_COMPARATOR

A combination of the vegetable bouillon, the microalgae and the beta-Glucan

Intervention Type DIETARY_SUPPLEMENT

14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae, Beta-Glucan (1.8g)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo vegetable bouillon

14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1,3g)

Intervention Type DIETARY_SUPPLEMENT

microalgae phaeodactylum

14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae Phaeodactylum

Intervention Type DIETARY_SUPPLEMENT

From the Microalgae phaeodactylum the extracted beta-Glucan (especially chrysolaminarin)

14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), Beta-Glucan (1.8g)

Intervention Type DIETARY_SUPPLEMENT

A combination of the vegetable bouillon, the microalgae and the beta-Glucan

14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae, Beta-Glucan (1.8g)

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Age ≥60 ≤90 years, weight ≥50 kg, generally healthy

* Signed informed consent form
* Willingness to follow the prescribed diet for the duration of the study
* No participation in any other clinical trial (current or within the last 30 days)

Exclusion Criteria

* Taking intestinal therapeutics, antibiotics, immunosuppressants or similar. (if necessary, decision on a case-by-case basis)
* Pregnancy/breastfeeding
* Relevant violations of the dietary protocol
* Occurrence of relevant diseases (if necessary, individual case decision)
* Withdrawal of consent
* Placement in a clinic or similar facility due to official or court order
Minimum Eligible Age

65 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Hohenheim

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Stephan C. Bischoff, MD, Professor

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Stephan C. Bischoff, Prof. Dr

Stuttgart, Baden-Wurttemberg, Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Stephan C Bischoff, Prof. Dr

Role: CONTACT

0711 459 24101

Lena Stiefvatter, M.SC

Role: CONTACT

071145924881

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MIA_E

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Brown Seaweed as a Breast Cancer Preventive
NCT01204957 COMPLETED PHASE1/PHASE2